Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 786 of 2,219.
    «« First « Previous 782  783  784  785  786  787  788  789  790  Next» Last»»
    EudraCT Number: 2013-002557-30 Sponsor Protocol Number: PRO/GLY/001 Start Date*: 2014-03-18
    Sponsor Name:Proveca Ltd
    Full Title: A two-staged, open label, single dose, two period, two-sequence, crossover study to compare the bioavailability of 2 mg Glycopyrronium Bromide from a new oral solution (2 mg/5 ml) (Test Product) wi...
    Medical condition: Sialorrhoea (chronic pathological drooling)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2013-004979-13 Sponsor Protocol Number: 2012-496 Start Date*: 2014-01-29
    Sponsor Name:Rigshospitalet, 2032
    Full Title: Treatment of Preoperative Anaemia in Patients with Urogenital Cancer: A Randomised Double-Blind Placebo-Controlled Study of Intravenous Iron Isomaltide 1000 Monofer© versus Saline
    Medical condition: Iron deficiency anaemia and anaemia of chronic disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004851 10022974 Iron deficiency anemia LLT
    17.1 100000004851 10020970 Hypochromic anaemia of chronic disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003343-35 Sponsor Protocol Number: CR-TFB-2014/502 Start Date*: 2014-10-01
    Sponsor Name:Thomas Fichtner Bendtsen
    Full Title: The effect of saphenous nerve and obturator nerve block combined with systemic high dose glucocorticoid versus local infiltration analgesia combined with a systemic high dose glucocorticoid on opi...
    Medical condition: The medical condition to be examined in this study is the first postoperative period after total knee replacement with a view to pain management.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10038286 Regional nerve block LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004324-11 Sponsor Protocol Number: NVALT-15 Start Date*: 2014-06-02
    Sponsor Name:Stichting NVALT studies
    Full Title: Phase II study with oral fibroblast growth factor-1 inhibitor BIBF1120 as second line treatment in lung carcinoma patients harboring fibroblast growth factor receptor-1 gene amplification (NVALT-15...
    Medical condition: Non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005073-37 Sponsor Protocol Number: I-1409 Start Date*: 2015-02-02
    Sponsor Name:Department of Nuclear Medicine, Aalborg University Hospital
    Full Title: 68Ga-PSMA PET/CT for detection of recurrent prostate cancer: Comparison with 18F-fluoride PET/CT, MRI and DW-MRI
    Medical condition: Patients diagnosed with biochemical (PSA) relapse following curative intended treatment (defined as radical prostatectomy or radiotherapy, either by external beam radiotherapy or low- or high-dose ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    17.1 100000004848 10036223 Positron emission tomography LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005161-72 Sponsor Protocol Number: V59P20 Start Date*: 2014-12-05
    Sponsor Name:Novartis Vaccines & Diagnostics
    Full Title: A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with One Dose of Licensed Meningococc...
    Medical condition: Prophylaxis for Neisseria meningitidis serogroup A, C, W, and Y
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002945-12 Sponsor Protocol Number: EFC12619 Start Date*: 2014-11-12
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: Six-month, Randomized, Open-label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Pe...
    Medical condition: Type1-Diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000175-43 Sponsor Protocol Number: A246 Start Date*: 2014-08-25
    Sponsor Name:AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO
    Full Title: CHemotherapy plus Enzalutamide In first line therapy for castration Resistant prOstate caNcer A multicentric Randomized phase II study. Ch.E.I.R.O.N. Trial
    Medical condition: castration Resistant prOstate caNcer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000281-21 Sponsor Protocol Number: H6Q-MC-S039 Start Date*: 2007-09-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter G...
    Medical condition: primary glioma without methylation of the promoter gene of MGMT enzyme
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003608-61 Sponsor Protocol Number: ZLB06_002CR Start Date*: 2015-01-05
    Sponsor Name:CSL Behring
    Full Title: A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency
    Medical condition: Primary Immune Deficiency
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005007-13 Sponsor Protocol Number: GS-US-352-1214 Start Date*: 2014-10-21
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibr...
    Medical condition: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002752-50 Sponsor Protocol Number: IC2014-10 Start Date*: 2014-12-05
    Sponsor Name:INSTITUT CURIE
    Full Title: Phase II clinical trial evaluating the efficacy of the dual inhibition of PIK/Akt/mTor signaling pathway by PF-05212384 (PKI-587) for patients with myeloid neoplasm secondary to chemo-radiotherapy ...
    Medical condition: Myeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) /or relapsed or refractory de novo AML /or de novo AML at diagnostic considered unfit to benefit from induction therapy with chemotherap...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10066572 AML progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004962-76 Sponsor Protocol Number: Solenne-OxoF-Rosa Start Date*: 2015-01-27
    Sponsor Name:Solenne BV
    Full Title: The treatment of Rosacea with Oxofulleram. A pilot study to assess the clinical applicability of Oxofulleram
    Medical condition: papulopustular rosacea
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001330-29 Sponsor Protocol Number: LENALID01 Start Date*: 2015-01-30
    Sponsor Name:Ernesto Pérez Persona
    Full Title: No
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003934-22 Sponsor Protocol Number: VLA84-201 Start Date*: 2014-12-10
    Sponsor Name:Valneva Austria GmbH
    Full Title: DOSE-CONFIRMATION, IMMUNOGENICITY AND SAFETY STUDY OF THE CLOSTRIDIUM DIFFICILE VACCINE CANDIDATE VLA84 IN HEALTHY ADULTS AGED 50 YEARS AND OLDER. RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE II S...
    Medical condition: Prevention against Clostridium difficile infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003421-28 Sponsor Protocol Number: TUD-HINKL1-059 Start Date*: 2014-07-10
    Sponsor Name:Technische Universität Dreden
    Full Title: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia
    Medical condition: Newly diagnosed high-risk AML other than acute promyelocytic leukemia, ≥20% blasts
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001637-88 Sponsor Protocol Number: 2014-650 Start Date*: 2014-08-12
    Sponsor Name:John Vissing
    Full Title: A phase 2a study to explore treatment with Sodium Valproate in adults with McArdle Disease (Glycogen Storage Disorder Type V, GSDV)
    Medical condition: McArdle disease (Glycogen storage disorder type V)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10026969 McArdle's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004371-22 Sponsor Protocol Number: ADN009 Start Date*: 2015-01-12
    Sponsor Name:ADIENNE SA
    Full Title: Phase IV study to assess, the effect of hepatic impairment on the pharmacokinetics of Thiotepa and the potential of Thiotepa to alter the QT interval in pedatric patients undergoing allogeneic haem...
    Medical condition: Patients with various hematological disease requiring Bone Marrow Transplantation, with Child-Pugh score A and B
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004992-21 Sponsor Protocol Number: V72P10E1 Start Date*: 2014-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l
    Full Title: A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.
    Medical condition: Prophylaxis against invasive meningococcal disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003416-23 Sponsor Protocol Number: CRAD001LDE43 Start Date*: 2012-03-12
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open label, single arm trial to evaluate patients with metastatic renal cell carcinoma treated with everolimus after failure of first line therapy with sunitinib or pazopanib
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038409 Renal cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 782  783  784  785  786  787  788  789  790  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 07:17:27 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA